Carlos Oo. Esquivel

Carlos Oo. Esquivel

Auto-generated profile, based on publicly available information

Carlos Oo. Esquivel

Division of Abdominal Transplantation, Department of Surgery, Stanford University School of Medicine, Stanford, CA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2007 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
MBMona Beaunoyer
Mona Beaunoyer
JVJason M. Vanatta
Jason M. Vanatta
MOMakoto Ogihara
Makoto Ogihara
DSDebra Strichartz
Debra Strichartz
GDGary Dahl
Gary Dahl
CECarlos O. Esquivel
Carlos O. Esquivel

1 March 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DHDaniel Huang
Daniel Huang
JHJoseph K Hoang
Joseph K Hoang
RKRubayet Kamal
Rubayet Kamal
Pei Chien TsaiPei Chien Tsai
Pei Chien Tsai
HTHidenori Toyoda
Hidenori Toyoda
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
PURPOSE: There are limited data on antiviral treatment utilization and its impact on long-term outcomes of hepatitis B virus (HBV)– and hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) after hepatic resection. We aimed to determine the utilization and impact of antivirals in HBV- and HCV-related HCC. METHODS: This cohort study included 1,906 participants (1,054 HBV-related HCC and 852 HCV-related HCC) from 12 international sites. All participants had HBV- or HCV-related HCC and underwent curative surgical resection. The primary outcome was the utilization of antiviral therapy, and the secondary outcome was long-term overall survival (OS). RESULTS: The mean (±standard deviation [SD]) age was 62.1 (±11.3) years, 74% were male, and 84% were Asian. A total of 47% of the total cohort received antiviral therapy during a mean (±SD) follow-up of 5.0 (±4.3) years. The overall antiviral utilization for participants with HBV-related HCC was 57% and declined over time, from 65% before 2010, to 60% from 2010 to 2015, to 47% beyond 2015, P < .0001. The overall utilization of antivirals for HCV-related HCC was 35% and increased over time, from 24% before 2015 to 74% from 2015 and beyond, P < .0001. The 10-year OS was lower in untreated participants for both HBV (58% v 61%) and HCV participants (38% v 82%; both P < .0001). On multivariable Cox regression analysis adjusted for relevant confounders, antiviral therapy initiated before or within 6 months of HCC diagnosis was independently associated with lower mortality in both HBV- (adjusted hazard ratio [aHR], 0.60 [95% CI, 0.43 to 0.83]; P = .002) and HCV-related HCC (aHR, 0.18 [95% CI, 0.11 to 0.31]; P < .0001). CONCLUSION: Antiviral therapy is associated with long-term survival in people with HBV- or HCV-related HCC who undergo curative resection but is severely underutilized.

24 January 2013 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
IKIrene K. Kim
Irene K. Kim
ANAnna‐Kaisa Niemi
Anna‐Kaisa Niemi
CKCasey Krueger
Casey Krueger
CBClark A. Bonham
Clark A. Bonham
WCWaldo Concepcion
Waldo Concepcion
CECarlos O. Esquivel
Carlos O. Esquivel

24 January 2013 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
AGAmy Gallo
Amy Gallo
CECarlos O. Esquivel
Carlos O. Esquivel

1 May 1999 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
CECarlos Esquivel
Carlos Esquivel
EKEmmet Keeffe
Emmet Keeffe
GGGabriel Garcia
Gabriel Garcia
JIJoanne Imperial
Joanne Imperial
MMMaria Millan
Maria Millan
SSSamuel So
Samuel So

14 October 2010 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
BLBrandy R. Lu
Brandy R. Lu
CECarlos O. Esquivel
Carlos O. Esquivel